EUCTR2020-000077-25-PL进行中（未招募）1 期
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease - TRAILBLAZER-ALZ 2
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-60 to 85 years of age inclusive, at the time of signing the informed consent,
- •-Gradual and progressive change in memory function reported by the participant or
- •informant for =6 months,
- •-An MMSE score of 20 to 28 (inclusive) at LEAD-IN SCREENING or COMPLETE SCREENING,
- •-An acceptable P-tau criterion, or historical positive AD pathology prior to complete screening,
- •-Meet flortaucipir F18 scan (central read) criteria,
- •-Meet florbetapir F18 scan (central read) criteria,
- •-Have a study partner who will provide written informed consent to participate, is in
- •frequent contact with the participant (defined as at least 10 hours per week), and will
- •accompany the participant to study visits or be available by telephone at designated
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1740
排除标准
- •-Significant neurological disease affecting the central nervous system other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson’s disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures),
- •-Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric,immunologic, or hematologic disease and other conditions that, in the investigator’s opinion, could interfere with the analyses in this study; or has a life expectancy of <24months,
- •-History of cancer within the last 5 years, with the exception of non-metastatic basal and/or squamous
- •cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with low risk of recurrence or spread,
- •-Participants with any current primary psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessment, or affect the participant’s ability to complete the study. Participants with history of schizophrenia or other chronic psychosis are excluded,
- •-History of clinically significant multiple or severe drug allergies, significant atopy, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis,and/or exfoliative dermatitis),
研究者
相似试验
已完成
2 期
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer's DiseaseJPRN-jRCT2080223944Eli Lilly Japan K.K.360
招募中
1 期
Donanemab in Early Symptomatic Alzheimer’s DiseaseEUCTR2020-000077-25-NLEli Lilly and Company1,736
已完成
3 期
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer*s DiseaseEarly Symptomatic Alzheimer's DiseaseAlzheimersenile psychosisNL-OMON52785Eli Lilly27
进行中（未招募）
2 期
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseAlzheimer DiseaseJPRN-jRCT2031210449Masaki Takeshi330
进行中（未招募）
1 期
Assessment of Safety, Tolerability, and Efficacy of (LY3372689) in Participants With Alzheimer’s DiseaseAlzheimer DiseaseMedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-000170-29-PLEli Lilly and Company340